Genmab

This study compares a new drug, Rina-S, to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has returned or worsened after prior treatment. About 660 participants will be randomly assigned to receive either Rina-S or standard chemo. The goa…

This study tests a new drug called epcoritamab combined with other cancer medicines in adults with Non-Hodgkin lymphoma, a rare blood cancer. The goal is to see if these combinations are safe and help shrink tumors. About 496 participants will receive different drug mixes based o…

This study tests a new drug called Rina-S in about 160 people with advanced gastrointestinal cancers that have spread or cannot be removed. The goal is to see if the drug can shrink tumors or stop them from growing. All participants receive the active drug, and the study lasts ab…

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if Rina-S can shrink tumors or stop them from growing. All participants receive the active drug, and treatment may continue as long as it helps and side effe…

This study tests a new drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 764 participants will receive th…

This early-stage trial tests a new antibody drug, GEN3018, in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or stopped responding to treatment. The main goal is to check safety and find the best dose. Up to 78 participants will…

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose; then refining that dose; and finally, checking how well the drug works in a specific canc…

This early-stage trial tests a new antibody called GEN1079 in about 121 people with certain advanced solid tumors. The main goal is to check safety and find the best dose. Participants receive the active drug, not a placebo, and are monitored closely with blood tests and scans ov…

This study tests whether adding the experimental drug epcoritamab to standard treatments (rituximab and lenalidomide) works better than standard chemo for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1095 adults will be randomly assigned to differ…

This study tests whether adding the experimental drug Rina-S to standard therapy helps keep ovarian cancer from coming back. About 528 people with platinum-sensitive ovarian cancer will receive either Rina-S alone, Rina-S plus bevacizumab, bevacizumab alone, or monitoring only. T…